← Patent-cliff monitor Loss of exclusivity February 2034 latest FDA-listed patent expiry
Drug detail Brand name FORZINITY Active ingredient ELAMIPRETIDE HYDROCHLORIDE Strength EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval September 2025 Marketing status RX
Listed patents Patent Expires Type 12268724 February 2034 use U-4277 11771734 February 2034 use U-4277 11083772 February 2034 use U-4277 11083771 February 2034 use U-4277 9687519 February 2034 use U-4277 7576061 January 2027 substance, product
Regulatory exclusivity Code Expires ODE-551 September 2032 NCE September 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.